Business Standard

Abbott India

Abbott India rises 4% on strong Q4 performance

Abbott India's profit jumped 24.1 per cent to Rs 287.1 crore in the March quarter of FY24 (Q4FY24), from Rs 231.4 crore in the March quarter of FY23 (Q4FY23)

Abbott India rises 4% on strong Q4 performance
Updated On : 10 May 2024 | 10:26 AM IST

Abbott India Q4 results: Profit rises 24% to Rs 287 cr, revenue up 7%

The drugmaker's revenue from operations increased to Rs 1,439 crore, a 7 per cent increase from the Rs 1,343 crore recorded in Q4 FY23

Abbott India Q4 results: Profit rises 24% to Rs 287 cr, revenue up 7%
Updated On : 09 May 2024 | 8:04 PM IST

How to trade F&O stocks with high rollovers in May; check key levels here

Technical outlook on stocks with high rollover to May series: Keep a tab on these key support and resistance levels while trading in these F&O stocks.

How to trade F&O stocks with high rollovers in May; check key levels here
Updated On : 26 Apr 2024 | 12:01 PM IST

Strong portfolio, slew of launches to help Abbott India outperform

The company's Year-on-Year revenue growth of 8.3% exceeded expectations and its top line was aided by a product mix led by therapies

Strong portfolio, slew of launches to help Abbott India outperform
Updated On : 08 Mar 2024 | 10:35 PM IST

Portfolio, new launches to help pharma company Abbott India's stock

Firm's revenues were in line with estimates and operational parameters better than expected

Portfolio, new launches to help pharma company Abbott India's stock
Updated On : 29 Feb 2024 | 1:47 PM IST

Abbott Q3 results: Profit rises 26% to Rs 311 cr on strong demand

The company, which makes popular antacid medicine Digene, said its profit rose to 3.11 billion rupees ($37.5 million) from 2.47 billion rupees a year earlier

Abbott Q3 results: Profit rises 26% to Rs 311 cr on strong demand
Updated On : 01 Feb 2024 | 6:48 PM IST

Abbott India warns of laxatives shortage in tussle with Goa regulator

The two laxative brands together have estimated annual sales of $70 million in India, healthcare data firm Pharmarack says

Abbott India warns of laxatives shortage in tussle with Goa regulator
Updated On : 22 Sep 2023 | 7:21 PM IST

Goa state warns Abbott India on antacid Digene license suspension

The state authorities have given Abbott seven days to respond to the notice to defend its position

Goa state warns Abbott India on antacid Digene license suspension
Updated On : 14 Sep 2023 | 5:37 PM IST

Abbott India recalls batches of Antacid Digene gel

In its letter, the DCGI warned that Digene may be unsafe and its use may result in adverse reaction

Abbott India recalls batches of Antacid Digene gel
Updated On : 07 Sep 2023 | 4:27 PM IST

Abbott recalls antacid Digene Gel made in Goa after consumer complaints

India's drugs regulator issues advisory against use; company says there is no 'health concern'

Abbott recalls antacid Digene Gel made in Goa after consumer complaints
Updated On : 07 Sep 2023 | 2:36 PM IST

Abbott India posts 41% rise in Q1 profit at Rs 29 crore on strong sales

The company has reported a double-digit growth in its revenue for the past three quarters, led by falling operating expenses and steady sales

Abbott India posts 41% rise in Q1 profit at Rs 29 crore on strong sales
Updated On : 09 Aug 2023 | 8:06 PM IST

Stocks to watch: Wipro, HUL, Axis Bank, Bajaj Finance, Tata Power, Abbott

Stocks to watch today: From Hindustan Unilever to Wipro, here are top stocks to watch in Thursday's trading session

Stocks to watch: Wipro, HUL, Axis Bank, Bajaj Finance, Tata Power, Abbott
Updated On : 27 Apr 2023 | 7:51 AM IST

5 mid-cap stocks hit crucial peaks, enter next bull run; Do you own any?

These 5 mid-cap stocks may rise up to 20 per cent, as technical charts reveal positive breakouts

5 mid-cap stocks hit crucial peaks, enter next bull run; Do you own any?
Updated On : 10 Apr 2023 | 12:31 PM IST

Key brands, new launches to sustain Abbott India's outperformance

Margins to remain healthy on the back of cost-saving measures

Key brands, new launches to sustain Abbott India's outperformance
Updated On : 14 Mar 2023 | 11:07 PM IST

Measuring worth: Front-row seats to high return-on-equity stocks

A portfolio of richly valued RoE stocks is expected to outperform the broader market over the longer term.

Measuring worth: Front-row seats to high return-on-equity stocks
Updated On : 09 Nov 2022 | 12:05 AM IST

Core brands, new launches to help Abbott India stock outperform: Analysts

Analysts expect double-digit growth for pharma major even if Q1 disappointed

Core brands, new launches to help Abbott India stock outperform: Analysts
Updated On : 14 Sep 2022 | 10:45 PM IST

Pharma company Abbott ties up with health tech firms for diabetes care

Abbott on Tuesday said it has tied up with health-tech firms like BeatO, Sugar.fit, PharmEasy, GOQii, 1MG and Zyla for diabetes care

Pharma company Abbott ties up with health tech firms for diabetes care
Updated On : 08 Feb 2022 | 5:07 PM IST

Strong growth rates expected to drive Abbott India's outperformance

New launches, power brands, digital initiatives to keep it ahead of peers

Strong growth rates expected to drive Abbott India's outperformance
Updated On : 22 Sep 2021 | 1:45 AM IST

Abbott introduces single-dose formulation of carbetocin in India

Drug major Abbott on Tuesday said it has launched room-temperature-stable, single-dose formulation of carbetocin in India to help in the prevention of postpartum haemorrhage (PPH)

Abbott introduces single-dose formulation of carbetocin in India
Updated On : 31 Aug 2021 | 3:24 PM IST

Abbott gets DCGI nod for once-a-day heart failure, angina treatment drug

Global healthcare firm Abbott on Wednesday said it has received approval from the Drugs Controller General of India (DCGI) for its once-a-day formulation, Ivabradine, used for treatment of chronic heart failure and chronic stable angina. The company plans to launch Ivabradine prolonged release tablets in the Indian market in the coming weeks, Abbott said in a statement. This formulation will be more convenient for patients, which will help facilitate treatment adherence with the aim to improve health outcomes, it added. The formulation has been developed at Abbott's innovation & development (I&D) centre in Mumbai, the statement said. "Adherence to therapy is a critical factor to maximize the overall health of people with chronic heart failure or chronic stable angina. We have used the best technology and science to develop this new dosage formulation," Abbott Regional Medical Director Balagopal Nair said. The convenient once-a-day formulation will help improve overall ...

Abbott gets DCGI nod for once-a-day heart failure, angina treatment drug
Updated On : 02 Sep 2020 | 4:17 PM IST